Finch_Short_Logo_L.png
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
10 mai 2023 07h00 HE | Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...
Finch_Short_Logo_L.png
Finch Therapeutics Announces Executive Leadership Transitions
25 avr. 2023 16h05 HE | Finch Therapeutics Group, Inc.
Matthew P. Blischak, an experienced life sciences executive and intellectual property counsel, appointed as Chief Executive Officer effective May 16, 2023; Mark Smith, PhD, to complete his time as CEO...
Finch_Short_Logo_L.png
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
18 avr. 2023 16h01 HE | Finch Therapeutics Group, Inc.
SOMERVILLE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch”, “Finch Therapeutics” or the “Company”) (Nasdaq: FNCH), a microbiome technology company with a portfolio...